Lilly revenue rises 7.2 pct on higher demand for new drugs
Eli Lilly and Co reported a 7.2 percent rise in quarterly revenue, lifted by higher demand for its diabetes drug Trulicity and other new treatments.
The drugmaker said net income rose to $771.8 million, or 73 cents per share, in the fourth quarter ended Dec. 31, from $478.4 million, or 45 cents per share, a year earlier.
Revenue rose to $5.76 billion from $5.38 billion.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd